Yes, we need to reduce dishonesty and corruption among our corporations, but we should look to our political class as well.

In October of 2009, Kumud Majumder, the father of an 11-year-old son with advanced leukemia, joined a lawsuit challenging the federal ban on compensating bone-marrow donors. He wanted to save his son's life. Last week Mr. Majumder and his co-plaintiffs enjoyed a victory. The U.S. Court of Appeals for the Ninth Circuit ruled that the majority of bone-marrow donors may lawfully be compensated.

While there is no such wide-ranging immigration reform bill currently making the rounds in Congress, the "Stopping Trained in America Ph.D.s from leaving the Economy" (S.T.A.P.L.E.) Act, sponsored by Rep. Jeff Flake (R-Ariz.) has bipartisan support and is a step in the right direction.

Our new research shows that, compared to illegal counterfeit pharmaceuticals, substandard legal medicines can pose an equally dangerous threat.

Following a defeat in Citizens United, the Obama administration is making an unprecedented assault on free speech through a proposed executive order requiring federal bidders to disclose their political giving during the previous two years.

Efforts to limit the commercial use of data on physician prescribing could have broad implications for regulatory programs that promote drug safety. At issue are a series of laws pursued by state legislators that would restrict access to information on the prescriptions written by individual doctors.

Constitutional law expert Michael Greve warns that overlooked cases, already before the Court and involving enormous amounts of money, have potentially huge implications for the future of ObamaCare.

The states' fiscal crisis is structural, not cyclical. Real recovery and reform will require drastic changes to our federal architecture.